MA55381A - Pyridazinones et leurs procédés d'utilisation - Google Patents
Pyridazinones et leurs procédés d'utilisationInfo
- Publication number
- MA55381A MA55381A MA055381A MA55381A MA55381A MA 55381 A MA55381 A MA 55381A MA 055381 A MA055381 A MA 055381A MA 55381 A MA55381 A MA 55381A MA 55381 A MA55381 A MA 55381A
- Authority
- MA
- Morocco
- Prior art keywords
- pyridazinones
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962821178P | 2019-03-20 | 2019-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55381A true MA55381A (fr) | 2022-01-26 |
Family
ID=72519163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055381A MA55381A (fr) | 2019-03-20 | 2020-03-18 | Pyridazinones et leurs procédés d'utilisation |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220152031A1 (fr) |
EP (1) | EP3941475A4 (fr) |
JP (1) | JP2022525506A (fr) |
CN (1) | CN113939295A (fr) |
AU (1) | AU2020240059A1 (fr) |
CA (1) | CA3132580A1 (fr) |
IL (1) | IL286481A (fr) |
MA (1) | MA55381A (fr) |
MX (1) | MX2021011316A (fr) |
SG (1) | SG11202109568TA (fr) |
WO (1) | WO2020191056A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY38377A (es) * | 2018-09-18 | 2020-04-30 | Goldfinch Bio Inc | Piridazinonas y sus métodos de uso |
IL299623A (en) * | 2020-07-03 | 2023-03-01 | Wuhan Ll Science And Tech Development Co Ltd | Heterocyclic compound and its use |
EP4400500A1 (fr) * | 2021-09-10 | 2024-07-17 | Medshine Discovery Inc. | Composé de pyridazinone à substitution halogène et son application |
CN114235972B (zh) * | 2021-10-28 | 2023-08-22 | 乳源东阳光药业有限公司 | 一种测定利格列汀杂质rbp-1含量的方法 |
WO2024027752A1 (fr) * | 2022-08-05 | 2024-02-08 | 武汉朗来科技发展有限公司 | Composition pharmaceutique comprenant un composé hétérocyclique, procédé de préparation associé et utilisation correspondante |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8901423D0 (en) * | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
GB9015764D0 (en) * | 1990-07-18 | 1990-09-05 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
CA2099743A1 (fr) * | 1992-07-02 | 1994-01-03 | Akihiko Ishida | Derives de la pyridazinone et procedes pour leur preparation |
EP0737193A1 (fr) * | 1993-12-29 | 1996-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Compose pyrazolopyridine antagoniste de l'adenosine |
JPH09216883A (ja) * | 1996-02-09 | 1997-08-19 | Fujisawa Pharmaceut Co Ltd | ピラゾロピリジン化合物および該化合物を含有する医薬 |
AUPQ441499A0 (en) * | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
US20050043315A1 (en) * | 2002-01-02 | 2005-02-24 | Hideo Tsutsumi | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
AU2003901647A0 (en) * | 2003-04-04 | 2003-05-01 | Fujisawa Pharmaceutical Co., Ltd. | Novel Condensed Furan Compounds and Pharmaceutical Use Thereof |
MXPA06008257A (es) * | 2004-01-23 | 2006-08-31 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos. |
CA2583536A1 (fr) * | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Antagonistes aux recepteurs de cgrp |
CN101232885A (zh) * | 2005-01-25 | 2008-07-30 | 神经能质公司 | 经取代的哒嗪基喹啉-4-基胺和嘧啶基喹啉-4-基胺类似物 |
ATE452635T1 (de) * | 2005-12-01 | 2010-01-15 | Hoffmann La Roche | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer |
JP2009518442A (ja) * | 2005-12-05 | 2009-05-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素インヒビターとして有益な置換ピラゾール化合物 |
DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007061963A1 (de) * | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
EP2265601B1 (fr) * | 2008-03-13 | 2012-02-01 | Bristol-Myers Squibb Company | Dérivés de la pyridazine inhibiteurs du facteur xia |
EP2288611B1 (fr) * | 2008-03-20 | 2013-05-15 | Amgen Inc. | Modulateurs d aurora kinase et procédé d utilisation |
DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
TW201444844A (zh) * | 2013-03-14 | 2014-12-01 | Hydra Biosciences Inc | 經取代之黃嘌呤及使用其之方法 |
EP2881390A1 (fr) * | 2013-12-04 | 2015-06-10 | Sanofi | Dérivés de thienométhylpipérazine en tant qu'inhibiteurs d'époxyde-hydrolase soluble |
WO2016023830A1 (fr) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione |
US20230203028A1 (en) * | 2017-09-18 | 2023-06-29 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
-
2020
- 2020-03-18 MX MX2021011316A patent/MX2021011316A/es unknown
- 2020-03-18 SG SG11202109568T patent/SG11202109568TA/en unknown
- 2020-03-18 EP EP20774183.6A patent/EP3941475A4/fr active Pending
- 2020-03-18 MA MA055381A patent/MA55381A/fr unknown
- 2020-03-18 JP JP2021549878A patent/JP2022525506A/ja active Pending
- 2020-03-18 WO PCT/US2020/023369 patent/WO2020191056A1/fr unknown
- 2020-03-18 AU AU2020240059A patent/AU2020240059A1/en active Pending
- 2020-03-18 US US17/440,928 patent/US20220152031A1/en active Pending
- 2020-03-18 CA CA3132580A patent/CA3132580A1/fr active Pending
- 2020-03-18 CN CN202080022397.8A patent/CN113939295A/zh active Pending
-
2021
- 2021-09-19 IL IL286481A patent/IL286481A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020191056A8 (fr) | 2021-09-30 |
CA3132580A1 (fr) | 2020-09-24 |
SG11202109568TA (en) | 2021-10-28 |
CN113939295A (zh) | 2022-01-14 |
AU2020240059A1 (en) | 2021-10-28 |
EP3941475A4 (fr) | 2023-01-25 |
IL286481A (en) | 2021-12-01 |
EP3941475A1 (fr) | 2022-01-26 |
US20220152031A1 (en) | 2022-05-19 |
JP2022525506A (ja) | 2022-05-17 |
MX2021011316A (es) | 2021-10-13 |
WO2020191056A1 (fr) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA55885A (fr) | Chélateurs macrocycliques et leurs procédés d'utilisation | |
MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
MA55381A (fr) | Pyridazinones et leurs procédés d'utilisation | |
MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA55301A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
MA54261A (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA53919A (fr) | Constructions d'acides nucléiques et procédés d'utilisation | |
MA54594A (fr) | Stéroïdes neuroactifs et leurs procédés d'utilisation | |
MA49520A (fr) | Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés d'utilisation |